XUNFEIHEALTH (02506) rallied sharply in Hong Kong trading, climbing nearly 20% intraday before settling with a 17.36% gain to HK$74.36, with turnover reaching HK$39.23 million.

The surge followed the company's release of its 2026 interim results on August 18, which showed first-half revenue of RMB 446 million, a 49.4% year-on-year increase that significantly exceeded market expectations. Gross profit rose 53.5% to RMB 236 million, with gross margin expanding 1.4 percentage points to 52.9%.

Segment performance revealed a strong growth trajectory across key business lines. The AI clinical assistant unit generated RMB 202 million in revenue, up 47.5% year-on-year, accounting for 45.2% of total revenue and maintaining its position as the company's stable core. Meanwhile, the AI health assistant segment delivered RMB 182 million in revenue, a substantial 74.9% jump that lifted its revenue share to 40.9%, making it the fastest-growing engine. The AI digital infrastructure business contributed RMB 62 million, reflecting a 7.9% increase.

As of the end of June, the company's products had reached 828 districts and counties across 31 provinces, serving more than 77,000 grassroots medical institutions and 727 grade-A hospitals nationwide.

Analysts suggest that with the continued rollout of the 15th Five-Year Plan's medical digitization policies, four key sectors—grassroots healthcare, hospitals, medical insurance, and domestic AI—are set to benefit simultaneously. The industry's construction cycle is well-defined, and the company's large-model technology advantages, combined with its validated commercialization model, position it for long-term earnings growth certainty.